Natural Product (NP) Details
| General Information of the NP (ID: NP0904) | |||||
|---|---|---|---|---|---|
| Name |
Ginsenoside
|
||||
| Species Origin | Panax ginseng ... | Click to Show/Hide | |||
| Panax ginseng | |||||
| Lepidine ( Lepidium sativum) | |||||
| Disease | Lung cancer [ICD-11: 2C25] | Phase 2 | [1] | ||
| Colon cancer [ICD-11: 2B90] | Investigative | ||||
| ADMET Property |
Absporption
Caco-2 Permeability
-4.959
MDCK Permeability
-4.903
PAMPA
+
HIA
- - -
Distribution
VDss
-0.198
PPB
95.3%
BBB
+++
Metabolism
CYP1A2 inhibitor
- - -
CYP1A2 substrate
- -
CYP2C19 inhibitor
- - -
CYP2C19 substrate
+++
CYP2C9 inhibitor
- -
CYP2C9 substrate
- -
CYP2D6 inhibitor
- - -
CYP2D6 substrate
- - -
CYP3A4 inhibitor
- - -
CYP3A4 substrate
+
CYP2B6 inhibitor
-
CYP2B6 substrate
- - -
CYP2C8 inhibitor
++
HLM Stability
- -
Excretion
CLplasma
13.497
T1/2
0.468
Toxicity
DILI
- - -
Rat Oral Acute Toxicity
-
FDAMDD
-
Respiratory
++
Human Hepatotoxicity
+
Ototoxicity
+
Drug-induced Nephrotoxicity
+
Drug-induced Neurotoxicity
- -
Hematotoxicity
- -
Genotoxicity
- -
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Herb ID | |||||
| SymMap ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Reorafenib | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
The synergistic inhibitory effect presented by the combination therapy was dependent on the gradient concentration and treatment time. | |||||
| Cyclophosphamide | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vivo Model | C57BL/6 mice were inoculated by subcutaneous injection in the right front axilla with 1 * 106 Lewis cells. | |||||
| Experimental
Result(s) |
Combination of Ginsenoside H dripping pills and cyclophosphamide improve paraneoplastic syndrome and inhibit postoperative recurrence via the reversion of Th1/Th2 shift. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Protein kinase C beta (PRKCB) | Molecule Info | [4] | |
| KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
| 2 | ErbB signaling pathway | |||
| 3 | Ras signaling pathway | |||
| 4 | Rap1 signaling pathway | |||
| 5 | Calcium signaling pathway | |||
| 6 | Chemokine signaling pathway | |||
| 7 | NF-kappa B signaling pathway | |||
| 8 | HIF-1 signaling pathway | |||
| 9 | Phosphatidylinositol signaling system | |||
| 10 | Sphingolipid signaling pathway | |||
| 11 | mTOR signaling pathway | |||
| 12 | Vascular smooth muscle contraction | |||
| 13 | Wnt signaling pathway | |||
| 14 | VEGF signaling pathway | |||
| 15 | Focal adhesion | |||
| 16 | Tight junction | |||
| 17 | Gap junction | |||
| 18 | Natural killer cell mediated cytotoxicity | |||
| 19 | B cell receptor signaling pathway | |||
| 20 | Fc epsilon RI signaling pathway | |||
| 21 | Fc gamma R-mediated phagocytosis | |||
| 22 | Leukocyte transendothelial migration | |||
| 23 | Circadian entrainment | |||
| 24 | Long-term potentiation | |||
| 25 | Retrograde endocannabinoid signaling | |||
| 26 | Glutamatergic synapse | |||
| 27 | Cholinergic synapse | |||
| 28 | Serotonergic synapse | |||
| 29 | GABAergic synapse | |||
| 30 | Dopaminergic synapse | |||
| 31 | Long-term depression | |||
| 32 | Inflammatory mediator regulation of TRP channels | |||
| 33 | Insulin secretion | |||
| 34 | GnRH signaling pathway | |||
| 35 | Melanogenesis | |||
| 36 | Thyroid hormone synthesis | |||
| 37 | Thyroid hormone signaling pathway | |||
| 38 | Oxytocin signaling pathway | |||
| 39 | Aldosterone-regulated sodium reabsorption | |||
| 40 | Endocrine and other factor-regulated calcium reabsorption | |||
| 41 | Salivary secretion | |||
| 42 | Gastric acid secretion | |||
| 43 | Pancreatic secretion | |||
| 44 | Carbohydrate digestion and absorption | |||
| 45 | Amphetamine addiction | |||
| 46 | Morphine addiction | |||
| 47 | Vibrio cholerae infection | |||
| 48 | Leishmaniasis | |||
| 49 | African trypanosomiasis | |||
| 50 | Amoebiasis | |||
| 51 | Hepatitis B | |||
| 52 | Influenza A | |||
| 53 | Pathways in cancer | |||
| 54 | Proteoglycans in cancer | |||
| 55 | MicroRNAs in cancer | |||
| 56 | Glioma | |||
| 57 | Non-small cell lung cancer | |||
| 58 | Choline metabolism in cancer | |||
| NetPath Pathway | IL2 Signaling Pathway | Click to Show/Hide | ||
| Panther Pathway | Alzheimer disease-amyloid secretase pathway | Click to Show/Hide | ||
| 2 | Angiogenesis | |||
| 3 | Apoptosis signaling pathway | |||
| 4 | B cell activation | |||
| 5 | EGF receptor signaling pathway | |||
| 6 | Endothelin signaling pathway | |||
| 7 | FGF signaling pathway | |||
| 8 | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||
| 9 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| 10 | Metabotropic glutamate receptor group I pathway | |||
| 11 | Muscarinic acetylcholine receptor 1 and 3 signaling pathway | |||
| 12 | VEGF signaling pathway | |||
| 13 | Wnt signaling pathway | |||
| 14 | 5HT2 type receptor mediated signaling pathway | |||
| 15 | Histamine H1 receptor mediated signaling pathway | |||
| 16 | Oxytocin receptor mediated signaling pathway | |||
| 17 | Thyrotropin-releasing hormone receptor signaling pathway | |||
| 18 | CCKR signaling map ST | |||
| Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | Click to Show/Hide | ||
| 2 | TCR signaling in naï | |||
| 3 | ||||
| 4 | TCR signaling in naï | |||
| 5 | ||||
| 6 | IL2-mediated signaling events | |||
| 7 | Ras signaling in the CD4+ TCR pathway | |||
| 8 | JNK signaling in the CD4+ TCR pathway | |||
| 9 | Regulation of Ras family activation | |||
| 10 | Downstream signaling in naï | |||
| Reactome | Disinhibition of SNARE formation | Click to Show/Hide | ||
| 2 | Activation of NF-kappaB in B cells | |||
| 3 | Trafficking of GluR2-containing AMPA receptors | |||
| 4 | G alpha (z) signalling events | |||
| 5 | Depolymerisation of the Nuclear Lamina | |||
| 6 | WNT5A-dependent internalization of FZD4 | |||
| 7 | VEGFR2 mediated cell proliferation | |||
| 8 | Response to elevated platelet cytosolic Ca2+ | |||
| WikiPathways | Calcium Regulation in the Cardiac Cell | Click to Show/Hide | ||
| 2 | Insulin Signaling | |||
| 3 | EGF/EGFR Signaling Pathway | |||
| 4 | Wnt Signaling Pathway | |||
| 5 | Wnt Signaling Pathway and Pluripotency | |||
| 6 | MAPK Signaling Pathway | |||
| 7 | Wnt Signaling Pathway Netpath | |||
| 8 | G Protein Signaling Pathways | |||
| 9 | Kit receptor signaling pathway | |||
| 10 | Myometrial Relaxation and Contraction Pathways | |||
| 11 | Signaling by the B Cell Receptor (BCR) | |||
| 12 | Oncostatin M Signaling Pathway | |||
| 13 | Corticotropin-releasing hormone | |||
| 14 | AGE/RAGE pathway | |||
| 15 | B Cell Receptor Signaling Pathway | |||
| 16 | Signaling Pathways in Glioblastoma | |||
| 17 | miRs in Muscle Cell Differentiation | |||
| 18 | Response to elevated platelet cytosolic Ca2+ | |||
| 19 | MicroRNAs in cardiomyocyte hypertrophy | |||
| 20 | Physiological and Pathological Hypertrophy of the Heart | |||